Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Trade Show

TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Like Receptor Agonists


TriSalus Life Sciences®, an emerging immuno-oncology company committed to transforming outcomes for patients with liver and pancreatic tumors, today announced data presented at the American Association of Cancer Research showing that regional delivery of oligodeoxynucleotide 2395 (ODN2395) activated the toll-like receptor 9 (TLR9), resulting in reduced tumor burden of liver metastases in mice.1

ODNs bind and activate TLR9 to initiate an immune response against certain cancer cells.2 TLR9 agonists (TLR9A) activate both the innate and adaptive immune systems, and play an important role in antiviral and anti-tumor immunity.3 TLR agonists have been administered via different routes based on the therapeutic purpose, however, delivery of TLR agonists into liver tumors by direct needle injection has been clinically challenging, particularly in the setting of a large tumor burden.

The pre-clinical study presented at AACR, conducted by Chandra C. Ghosh and fellow researchers at Roger Williams Medical Center, examined the impact of metastatic liver disease in 12 mice, which were randomized to receive either 1, 3, 10 or 30 micrograms of the TLR9A, ODN2395, through the portal vein (PV) or 30 micrograms administered intravenously (IV). The study showed regional delivery of the TLR9A through the PV at the 30 micrograms dose level was superior to systemic IV administration with respect to control of liver metastases and reduction of liver myeloid-derived suppressor cells (MDSC), which play a crucial role in solid tumor immunosuppression, in addition to favorable effects on liver macrophage subsets.

"Understanding the impact of delivery route on the ability of TLR9 agonists to control liver metastases and favorably modulate the immune microenvironment may help unleash the potential to use the immune system to fight cancer," said Steven Katz, M.D., Chief Medical Officer, TriSalus Life Sciences. "This foundational work will help us tap into the potential of integrating novel therapeutics with drug delivery technology to better penetrate solid tumors."

Solid tumors continue to represent one of the single biggest hurdles to successful cancer treatment.4 High levels of pressure inside solid tumors prevent the delivery of oncology therapeutics, with less than 1% of therapy penetrating solid tumors in some circumstances.5,6 TriSalus developed PEDD to deliver immuno-oncology therapeutics directly into the vasculature of solid tumors with the potential for minimizing systemic toxicity.

About TriSalus

TriSalus Life Sciences is a revenue generating, emerging immuno-oncology company dedicated to developing immunotherapy treatments for liver and pancreatic tumors using novel delivery technologies to improve patient outcomes. TriSalus intends to pursue multiple solid tumor indications with investigational SD-101 and acquire other immuno-oncology agents to combine with its proprietary Pressure-Enabled Drug Delivery technology for the administration of therapeutics intravascularly into visceral organ solid tumors. In combination with checkpoint inhibitors, TriSalus' focus is to reprogram the dominant immunosuppressive cell population in liver and pancreatic tumors. This innovative approach in development has the potential to leverage multiple mechanisms that can work together with the goal to overcome inherent immune suppression within the solid tumor microenvironment.

For more information, please visit www.trisaluslifesci.com.

  1. Gosh, Chandra S. et al. Regional administration of Class C CpG Oligodeoxynucleotides results in superior intrahepatic TLR9 activation and immunomodulation compared to systemic infusion. AACR Poster April, 2021.
  2. Shirota, Hidekazu, and Dennis M. Klinman. 2012. "Effect of CpG ODN on Monocytic Myeloid Derived Suppressor Cells." Oncoimmunology 1 (5): 780?82.
  3. Krieg, Arthur M. 2007. "Development of TLR9 Agonists for Cancer Therapy." The Journal of Clinical Investigation 117 (5): 1184?94.
  4. Jain, Rakesh K. 1994. "Barriers to Drug Delivery in Solid Tumors." Scientific American, 8.
  5. Wilhelm, Stefan, Anthony J. Tavares, Qin Dai, Seiichi Ohta, Julie Audet, Harold F. Dvorak, and Warren C. W. Chan. 2016. "Analysis of Nanoparticle Delivery to Tumours." Nature Reviews Materials 1 (5): 16014. https://doi.org/10.1038/natrevmats.2016.14.
  6. Sheth, Rahul A., Robin Hesketh, David S. Kong, Stephan Wicky, and Rahmi Oklu. 2013. "Barriers to Drug Delivery in Interventional Oncology." Journal of Vascular and Interventional Radiology 24 (8): 1201?7. https://doi.org/10.1016/j.jvir.2013.03.034.

 


These press releases may also interest you

at 05:12
NOTICE IS HEREBY GIVEN that THE EXTRAORDINARY GENERAL MEETING ("EGM") of Kindred Group plc (C 39017)  (the "Company") convened in terms of article 135 (1)(b) of the Companies Act (Cap.386 of the Laws of Malta) will be held on Thursday 10 June 2021 at...

at 05:00
via InvestorWire ? Today, WAX announced partnerships with a number of the world's most well-loved entertainment brands to release digital collectibles, called NFTs, on the WAX blockchain, including: Robotech (Funimation and Harmony Gold)Five Nights...

at 05:00
Canadian biogas experienced a decade of rapid growth from 2011 to 2020, with an almost 50% jump in operating biogas projects across the country. That's the key takeaway from the Canadian 2020 Biogas Market Report just released by the Canadian Biogas...

at 05:00
With UK businesses hoping to welcome the return of workers as soon as government guidelines allow, there's one element they need to be sure they don't miss in between their COVID-security preparations ? having the right connectivity in place so staff...

at 05:00
The9 Limited ("The9"), an established Internet company, today announced that it signed three Chia (XCH) cryptocurrency mining machine purchase and cloud service leasing agreements with three unrelated vendors, with the total contract sum of more...

at 05:00
Thanks to the high quality and performance of Firecomms products, Imperix is able to reinforce its leading position on the market of prototyping solutions for wide bandgap power converters. Imperix has grown a multi-disciplinary product portfolio on...



News published on 14 april 2021 at 09:30 and distributed by: